Although many studies have addressed the prognostic value of programmed cell death-
ligand 1 (PD-L1) expression in lung cancer, the results remain controversial. A systematic …

Background Observational studies on the prognostic role of programmed cell death-ligand 1
(PD-L1) in non-small cell lung cancer (NSCLC) are controversial. Methods To clarify the …

Background We conducted a meta-analysis to systematically evaluate the relationship
between programmed death-ligand 1 (PD-L1) expression and survival in patients with lung …

Background A meta-analysis was conducted to investigate the much-debated relationship
between the gene expression of programmed cell death-ligand 1 (PD-L1) and cancer …

Objective Programmed cell death 1 (PD-1) and one of its ligands, PD-L1, are key immune
checkpoint proteins. Evidences showed PD-L1 is an emerging biomarker for immunotherapy …

Objective To assess the association between PD-L1 expression and driver gene mutations
in patients with non-small-cell lung cancer (NSCLC). Method We performed a meta-analysis …

Background Several clinical trials have shown that immune treatment focus on programmed
death-1 and programmed death-ligand 1 (PD-L1) yields a good clinical efficacy in advanced …

Background Programmed death ligand-1 (PD-L1) is a predictive marker of anti-programmed
death protein 1 (PD-1)/PD-L1 therapies for non-small cell lung cancer (NSCLC). However …

Introduction The clinicopathological features of carcinomas expressing programmed death
ligand 1 (PD-L1) and their associations with common driver mutations, such as mutations in …

Background Programmed cell death-ligand 1 (PD-L1) is expressed in a group of cancers
that may be suitable targets for specific immunotherapy. This study investigated the …